Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes

Khan and Lanktree discuss glucagon-like peptide-1 (GLP-1) receptor agonists for treating chronic kidney disease in patients with type 2 diabetes. GLP-1 receptor agonists (also called "glutides") are an effective treatment for patients with type 2 diabetes and chronic kidney disease. They are a second-line treatment for patients with type 2 diabetes and chronic kidney disease. GLP-1 receptor agonists should not be used in combination with dipeptidyl peptidase 4 inhibitors.